This means that either the RAS mutation, or the combination of high CRLF2 and hyperphosphorylated JAK2 (including mutated JAK2) can explain the mechanism for high RAS activity in 12/14 (86%) of DS-ALL with high RAS activity. This evidence concerns the gene CRLF2 and acute lymphoblastic leukemia.